期刊文献+

Liquid chromatography coupled with mass spectrometry method for the simultaneous quantification of irbesartan and hydrochlorothiazide in human plasma 被引量:2

液质联用法测定人血浆中厄贝沙坦和氢氯噻嗪浓度(英文)
原文传递
导出
摘要 A simple and sensitive high-performance liquid chromatography mass spectrometry(LC-MS)method for the simultaneous determination of irbesartan and hydrochlorothiazide in human plasma was developed and applied to a pharmacokinetic study. Acetaminophen was used as the internal standard(IS).Sample pretreatment using liquid-liquid extraction with ethyl acetate was used.The analysis was carried out on an Elite SinoChrom ODS-BP C_(18)column with a mobile phase composed of acetonitrile-water (35:65,v/v).Target ions were [M-H]^-m/z 427.25 for irbesartan,[M-H]^-m/z 295.95 for hydrochlorothiazide and [M-H]^- m/z 150.05 for the IS via an electrospray ionization(ESI)source.The intra-and inter-day precision(RSD%)was below 14.5% for irbesartan and hydrochlorothiazide,and the accuracy(RE%)was less than 1.9% and-2.0% for irbesartan and hydrochlorothiazide,respectively.The linear calibration curves were obtained in the concentration range of 10-5000 ng/mL (r0.99)for irbesartan and 1-200 ng/mL(r0.99)for hydrochlorothiazide with the lower limit of quantification(LLOQ)of 10 ng/mL and 1 ng/mL,respectively.The method was applied to a clinical pharmacokinetic study of a tablet containing irbesartan and hydrochlorothiazide in healthy Chinese volunteers after oral administration. 建立了适用于测定人血浆中厄贝沙坦和氢氯噻嗪浓度的液相色谱-质谱(LC-MS)法,并将其应用于厄贝沙坦氢氯噻嗪人体药代动力学研究。人血浆样品采用液-液萃取法提取,内标为对乙酰氨基酚。采用依利特C_(18)柱,以乙腈-水(35:65,v/v)为流动相,选择离子监测负离子模式检测,厄贝沙坦m/z为427.25,氢氯噻嗪m/z为295.95,内标对乙酰氨基酚m/z为150.05。厄贝沙坦和氢氯噻嗪的日内和日间精密度(RSD%)均低于14.5%,准确度(RE%)分别低于1.9%和-2.0%。厄贝沙坦在10-5000ng/mL浓度范围内线性关系良好(r>0.99),氢氯噻嗪在1-200ng/mL浓度范围内线性关系良好(r>0.99)。所建立的方法已成功应用于厄贝沙坦氢氯噻嗪人体药代动力学研究。
出处 《Journal of Chinese Pharmaceutical Sciences》 CAS 2011年第4期360-367,共8页 中国药学(英文版)
关键词 HPLC-MS IRBESARTAN HYDROCHLOROTHIAZIDE PHARMACOKINETICS Human plasma HPLC-MS 厄贝沙坦 氢氯噻嗪 药代动力学 人血浆
  • 相关文献

参考文献15

  • 1Croom, K.F.; Curran, M.P.; Goa, K.L.; Perry, C.M. Drugs. 2004, 64, 999-1028.
  • 2Huang, Z.H. Chin. J. New Drugs Clin. Rem. 2006, 26, 384-387.
  • 3Wellington, K.; Faulds, D. Drugs. 2002, 62, 1983-2005.
  • 4Lant, A. Drugs. 1985, 29, 162-188.
  • 5Ashok, K.S.; Yusuf, M.; Omran, M.O.J. Chromatogr B. 2007, 848, 245-250.
  • 6Hsieh, J.Y.K.; Lin, C.; Matuszewski, B.K.; Dobrinska, M.R.J. Pharm. Biomed. Anal. 1994, 12, 1555 1562.
  • 7Ding, Y.B.; Fang, X.L.; Shen, J.E; Wang, X.Q.J. Chin. Pharm. Univ. 2005, 36, 551-555.
  • 8Lian, J.W.; Deng, X.X.; Wang, Z.W.; Bi, K.S.; Chen, X.H. Chin. J. Clin. Pharm. 2008, 17, 105-108.
  • 9Gonzalez, L.; Lopez, J.A.; Alonso, R.M.; Jimenez, R.M. J. Chromatogr. A. 2002, 949, 4940.
  • 10[ Chang, S.Y.; Whigan, N.V.; Rajesh, E J. Chromatogr B. 1997, 702, 149-155.

同被引文献12

引证文献2

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部